Key Points
- Insider sale: SVP Rhonda Farnum sold 31,067 shares on March 16 at an average price of $13.96 for about $433,695, trimming her position by 11.78% to 232,699 shares (≈$3.25M).
- Stock snapshot: TBPH opened at $13.83, trading below its 50‑day ($18.20) and 200‑day ($16.86) moving averages, with a 12‑month range of $7.90–$21.03 and a market cap of roughly $700.8M (P/E 24.26).
- Analyst sentiment: Ratings are mixed—several downgrades and lower price targets offset by some buy ratings—resulting in a consensus of "Moderate Buy" and an average price target of $22.60.
Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Theravance Biopharma Stock Down 0.6%
NASDAQ:TBPH opened at $13.83 on Thursday. The company's 50 day moving average is $18.20 and its 200-day moving average is $16.86. Theravance Biopharma, Inc. has a 12 month low of $7.90 and a 12 month high of $21.03. The firm has a market cap of $700.77 million, a price-to-earnings ratio of 24.26 and a beta of 0.17.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Oppenheimer downgraded shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating in a report on Thursday, March 5th. BTIG Research lowered their price target on Theravance Biopharma from $40.00 to $21.00 and set a "buy" rating on the stock in a research report on Tuesday, March 3rd. Wall Street Zen lowered Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 3rd. HC Wainwright boosted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Finally, B. Riley Financial restated a "neutral" rating and set a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $22.60.
View Our Latest Research Report on TBPH
Hedge Funds Weigh In On Theravance Biopharma
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in Theravance Biopharma during the 1st quarter valued at $101,000. Jane Street Group LLC grew its position in Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after purchasing an additional 88,540 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Theravance Biopharma during the 2nd quarter worth about $219,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Theravance Biopharma during the 2nd quarter worth about $624,000. Finally, Geode Capital Management LLC raised its position in shares of Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company's stock valued at $9,863,000 after buying an additional 3,416 shares during the last quarter. Institutional investors own 99.10% of the company's stock.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
